Aclaris Therapeutics ACRS Sale Of Stock Consideration Received On Transaction
Sale Of Stock Consideration Received On Transaction at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SaleOfStockConsiderationReceivedOnTransaction.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's sale of stock consideration received on transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's sale of stock consideration received on transaction?
- Aclaris Therapeutics (ACRS) reported sale of stock consideration received on transaction of $57.88M in Q1 2026.
- What is the long-term trend for Aclaris Therapeutics's sale of stock consideration received on transaction?
- Over 2 years (2022 to 2024), Aclaris Therapeutics's sale of stock consideration received on transaction has grown at a 1.5% compound annual growth rate (CAGR), from $72.74M to $74.91M.
- What does sale of stock consideration received on transaction mean?
- This represents the cash proceeds received from the issuance of equity securities to investors or strategic partners. It serves as a primary indicator of the company's ability to access capital markets to fund operations or growth initiatives. High levels of this activity may indicate a reliance on external financing to sustain clinical-stage development.